Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Sofosbuvir/velpatasvir regimen promises an effective pan-genotypic hepatitis C virus cure.

Drug design, development and therapy - 1 Jan 2017

Mir Fazia, Kahveci Alp S, Ibdah Jamal A, Tahan Veysel

Abstract excerpt

Hepatitis C virus (HCV) is a global pandemic, with nearly 200 million infected patients worldwide. HCV is the most common blood-borne infection in the US with numerous health implications including liver fibrosis, cirrhosis, and hepatocellular cancer. Traditional genotype-based HCV therapies with interferon resulted in moderate success in the sustained elimination of viral genome. Recent clinical trials of the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiviral Agents
Share to Carbamates
Share to Genotype

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hepatitis B Virus Studies

Share to Hepatitis C, Chronic

Share to Hepatitis C virus research

Share to Heterocyclic Compounds, 4 or More Rings

Share to Sofosbuvir

Source

Open in PubMed Open full text

Identifiers

PMID: 28260862
DOI: 10.2147/DDDT.S130945
PMCID: PMC5330188

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Sofosbuvir/velpatasvir regimen promises an effective pan-genotypic hepatitis C virus cure.PMID 28260862Read ↗

Sofosbuvir-velpatasvir: A single-tablet treatment for hepatitis C infection of all genotypes.Semantic proximity Read ↗

A pangenotypic, single tablet regimen of sofosbuvir/velpatasvir for the treatment of chronic hepatitis C infection.Semantic proximity Read ↗

Sofosbuvir and velpatasvir for the treatment of hepatitis C.Semantic proximity Read ↗

Pharmacokinetic drug evaluation of velpatasvir plus sofosbuvir for the treatment of hepatitis C virus infection.Semantic proximity Read ↗

Sofosbuvir/Velpatasvir: The First Pangenotypic Direct-Acting Antiviral Combination for Hepatitis C.Semantic proximity Read ↗

Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection.Semantic proximity Read ↗

Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in Patients With Hepatitis C Virus Genotype 2, 3, 4, or 6 Infections in an Open-Label, Phase 2 Trial.Semantic proximity Read ↗

Sofosbuvir and Velpatasvir: A complete pan-genotypic treatment for HCV patients.Semantic proximity Read ↗

Safety and efficacy of sofosbuvir plus velpatasvir with or without ribavirin for chronic hepatitis C virus infection: A systematic review and meta-analysis.Semantic proximity Read ↗

Efficacy of the Combination of Sofosbuvir, Velpatasvir, and the NS3/4A Protease Inhibitor GS-9857 in Treatment-Naïve or Previously Treated Patients With Hepatitis C Virus Genotype 1 or 3 Infections.Semantic proximity Read ↗

[Twelve-week of sofosbuvir/velpatasvir therapeutic regimen for chronic hepatitis C patients in northwest region of China: a real-world multicenter clinical study].Semantic proximity Read ↗

Sofosbuvir Plus Velpatasvir Combination Therapy for Treatment-Experienced Patients With Genotype 1 or 3 Hepatitis C Virus Infection: A Randomized Trial.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.